Patent · US Active

Preparation methods for a novel generation of biological safe KLH products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents

US10800820B2 · kind B2 · utility

0Cited by

0References

18Claims

0Family size

Assignee

Biosyn Arzneimittel GmbH · DE

Inventors

Ortwin Kottwitz · Ditzingen, DE
Thomas Stiefel · Stuttgart, DE
Shammana N. Muddukrishna · Carlsbad, US

Key dates

Filing date	Jun 12, 2014
Grant date	Oct 13, 2020
Priority date	—
Expiry date	Jun 12, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/6081
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the provision of a biologically safe hemolymph sera, preferably hemocyanin, more preferably KLH (keyhole limpet hemocyanin). The hemocyanin is purified using anion exchange chromatography.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.